It is better for all Israeli haters to hope that the Israelis will forgive if they are affected by cancer because if it turns out that a new report from Israel is real, the scientists from the Jewish state have discovered. medicine. And not only a cure for some forms of cancer, but a complete cure for deadly disease.
According to Dan Aridor, Chairman of the Board of Rapid Evolutionary Biotechnology Ltd. (AEBi) and Chief Executive Officer Illen Morad, their treatment will not take time to organize his body before he starts work. "We believe we will offer a full cure for cancer for one year. … Our cancer treatment will be effective from day one … and there will be no or minimal side effects at much lower costs than most other treatments on the market. Our solution will be both generic and personal. "
As reported by Jerusalem," According to the International Agency for Research on Cancer in the world, 1
The treatment is called MuTaTo (a multi-mouse toxin) and works a lot like antibiotics to deal with bacteria. MuTaTo is based on SoAP technology, which works by detecting, binding and removing bacteria by using bacteriophage-derived proteins. Bacteriophages are viruses that infect bacteria.
MuTaTo inserts DNA encoding a protein into a bacteriophage. Once inside, the protein appears on the surface of the phage, making it obvious to researchers who can use phages to find interactions with other proteins, DNA sequences and small molecules. Unlike Nobel Prize-winning scientists from 2018, George Smith and Gregory Wynter, who used phage display to develop new proteins or antibodies, the Israelis produce peptides that according to Morad are better prepared for work because they are – Less, cheaper and less difficult for
Morad said the company's initial efforts include trying to find "separate new peptides for specific types of cancer." But then he and colleague Dr Hannan Ichatchi decided to go for a break. He explained that most anticancer drugs attack a specific target on or within the cancer cell, but often cause a mutation that makes the drug ineffective. But MuTato, as noted by Jerusalem Post, uses a combination of several cancer-targeted peptides for each cancer cell at the same time combined with a strong peptide toxin that would specifically kill cancer cells. "
Morad said the company's technique "ensures that treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors escape from cancer … The probability of multiple mutations that would modify all target receptors simultaneously reduces drastically the number of targets used. Instead of attacking the receptors one by one, we attack the receptors three at a time – even the cancer can not mutate three receptors at once. "
Morad said MuTato, because it attacks many targets, destroys proteins that target cancer. cell. Morad also said MuTaTo peptide parts are small and flexible, they can penetrate areas where other drugs can not reach. He said: "This should make the entire molecule non-immunogenic in most cases and would allow re-administration of the drug."
Morad said treatment can reduce the side effects that often occur because cancer treatment is associated with wrong or additional goals or the proper goals of healthy cells. Aridor concluded: "Our results are consistent and repetitive."